Fig. 7: Treatment with DOX (CPT-SAHA)/pre-siiRhom PCL-CP NPs led to enhanced therapeutic efficacy and improved TIME.

Changes in tumor volumes (a) and body weights (b) in mice bearing 4T1 orthotopic tumors receiving various treatments. n = 5 animals. c Representative flow cytometric analysis and the quantification of the relative abundance of CD8⁺ T-cells, CD4⁺ T-cells, CD8⁺ IFNγ⁺ T-cells, CD8⁺ Granzyme B⁺ T-cells and CD8⁺ PD1⁺ T-cells in 4T1 tumor tissues after various treatments. n = 8 biologically independent samples. Changes in tumor volumes (d) and body weights (e) in mice bearing CT26 tumors receiving various treatments. n = 5 animals. f Flow cytometric analysis and the quantification of the relative abundance of CD8⁺ T-cells, CD4⁺ T-cells, CD8 ⁺ IFNγ⁺ T-cells, CD8⁺ Granzyme B⁺ T-cells and CD8⁺ PD1⁺ T-cells in CT26 tumor tissues after various treatments. n = 8 biologically independent samples. g Histogram and the quantitative analysis of MHCI expression in CT26 tumor tissues after various treatments. n = 3 biologically independent samples. h Tumor growth inhibition and survival of CT26 tumor-bearing mice receiving various treatments. n = 8 animals. Data are presented as mean ± s.e.m. in all panels. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test for comparison in (a, b, c, d, e, f, g, h (left)) and log rank test for comparison in (h) (right). Data are representative of two independent experiments in (a–h). Source data are provided as a Source Data file for (a–h).